ATE400649T1 - Neues verfahren zur induktion von zellulären seneszenz und screening-verfahren für ein mittel gegen alterung - Google Patents

Neues verfahren zur induktion von zellulären seneszenz und screening-verfahren für ein mittel gegen alterung

Info

Publication number
ATE400649T1
ATE400649T1 AT02746067T AT02746067T ATE400649T1 AT E400649 T1 ATE400649 T1 AT E400649T1 AT 02746067 T AT02746067 T AT 02746067T AT 02746067 T AT02746067 T AT 02746067T AT E400649 T1 ATE400649 T1 AT E400649T1
Authority
AT
Austria
Prior art keywords
protein
aging
cells
sensence
aging agent
Prior art date
Application number
AT02746067T
Other languages
English (en)
Inventor
Fuyuki Ishikawa
Original Assignee
Fuyuki Ishikawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuyuki Ishikawa filed Critical Fuyuki Ishikawa
Application granted granted Critical
Publication of ATE400649T1 publication Critical patent/ATE400649T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating And Analyzing Materials By Characteristic Methods (AREA)
AT02746067T 2001-07-16 2002-07-15 Neues verfahren zur induktion von zellulären seneszenz und screening-verfahren für ein mittel gegen alterung ATE400649T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001215576 2001-07-16
JP2001286412 2001-09-20

Publications (1)

Publication Number Publication Date
ATE400649T1 true ATE400649T1 (de) 2008-07-15

Family

ID=26618801

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02746067T ATE400649T1 (de) 2001-07-16 2002-07-15 Neues verfahren zur induktion von zellulären seneszenz und screening-verfahren für ein mittel gegen alterung

Country Status (8)

Country Link
US (1) US7291499B2 (de)
EP (1) EP1408109B1 (de)
JP (1) JPWO2003008577A1 (de)
AT (1) ATE400649T1 (de)
CA (1) CA2454873C (de)
DE (1) DE60227524D1 (de)
DK (1) DK1408109T3 (de)
WO (1) WO2003008577A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011045334A (ja) * 2009-08-28 2011-03-10 Kyushu Univ 細胞老化関連因子
FR2971792B1 (fr) * 2011-02-18 2017-06-23 Isp Investments Inc Methode in vitro pour identifier des agents modulateurs de la senescence cellulaire

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09271395A (ja) 1996-04-02 1997-10-21 Nippon Zoki Pharmaceut Co Ltd 内皮細胞を用いたスクリーニング法
EP0914450A1 (de) 1996-05-20 1999-05-12 Signal Pharmaceuticals, Inc. Mitogenaktivierte proteinkinase p38-2 und methoden zu deren verwendung
WO1998005761A1 (en) 1996-08-07 1998-02-12 The General Hospital Corporation Age-1 polypeptides and related molecules and methods
CN1254376A (zh) 1996-10-01 2000-05-24 杰龙公司 端粒酶逆转录酶
US7122360B1 (en) 1998-06-24 2006-10-17 University Of Dundee Polypeptides, polynucleotides and uses thereof
WO2000000491A1 (en) 1998-06-29 2000-01-06 The Regents Of The University Of California Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents

Also Published As

Publication number Publication date
CA2454873C (en) 2013-10-01
CA2454873A1 (en) 2003-01-30
US20050288216A1 (en) 2005-12-29
US7291499B2 (en) 2007-11-06
EP1408109B1 (de) 2008-07-09
DK1408109T3 (da) 2008-10-06
WO2003008577A1 (en) 2003-01-30
JPWO2003008577A1 (ja) 2004-11-11
EP1408109A1 (de) 2004-04-14
EP1408109A4 (de) 2005-02-16
DE60227524D1 (de) 2008-08-21

Similar Documents

Publication Publication Date Title
Finlayson et al. [3H] dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen
Sugiura et al. MARCKS-like protein is an initiating molecule in axolotl appendage regeneration
Feldmann Jr et al. Stem cell proteomes: a profile of human mesenchymal stem cells derived from umbilical cord blood
Kletsas et al. Effect of protein kinase inhibitors on the stretch‐elicited c‐Fos and c‐Jun up‐regulation in human PDL osteoblast‐like cells
Sancho-Bru et al. Genomic and functional characterization of stellate cells isolated from human cirrhotic livers
ATE474915T1 (de) Verfahren zur induktion der entwicklung und terminalen differenzierung von gedächtnis-b- zellen
DK1198585T3 (da) Fremgangsmåde til karakterisering af en biologisk tilstand ved anvendelse af kalibrerede genudtrykkelsesprofiler
DE602005013957D1 (de) Verfahren zur durchführung von vollbluttests
DE69922269D1 (de) IL-1 Rezeptor Fusionsproteine verwendet als Antagoniste und Verfahren zu deren Verwendung und Herstellung
DE60223644D1 (de) Feststoffbrenner, Verfahren zur Verwendung desselben, Brennkessel und Verfahren für dessen Betrieb
Decramer et al. Non-invasive markers of ureteropelvic junction obstruction
ATE541054T1 (de) Bio-barcode erkennung für zielmoleküle
Demou et al. Microgenomics profile the endogenous angiogenic phenotype in subpopulations of aggressive melanoma
Iosef et al. Quantitative proteomics reveal lineage-specific protein profiles in iPSC-derived Marfan syndrome smooth muscle cells
Eviatar et al. Synthesis of insulin‐like growth factor binding protein 3 in vitro in human articular cartilage cultures
Rosmark et al. Alveolar epithelial cells are competent producers of interstitial extracellular matrix with disease relevant plasticity in a human in vitro 3D model
Ryan et al. In vitro senescence and senolytic functional assays
Buckenmeyer et al. A 3D self-assembly platform integrating decellularized matrix recapitulates in vivo tumor phenotypes and heterogeneity
EA200100160A1 (ru) Новые способы идентификации биомолекул лигандов и мишеней
Gulati et al. Localization of bone morphogenetic protein 13 in human intervertebral disc and its molecular and functional effects in vitro in 3D culture
DE602004017884D1 (de) Fluoreszenzsonden zur verwendung bei einem bindungsassay auf proteinkinaseinhibitoren
DE60227524D1 (de) Neues verfahren zur induktion von zellulären seneszenz und screening-verfahren für ein mittel gegen alterung
BRPI0512798A (pt) molécula de ácido nucleico recombinante, célula, método para produzir uma proteìna de interesse, uso de uma seqüência de ácido nucleico tendo atividade anti-repressora, métodos para gerar uma célula hospedeira expressando dois polipeptìdios de interesse, e para expressar dois polipeptìdios de interesse
ATE428771T1 (de) Antikörper gegen hundepankreaslipase
ATE483981T1 (de) Verfahren, zusammensetzungen und verbindungstests zur hemmung der amyloid-beta-proteinproduktion

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties